Full Text View
Tabular View
No Study Results Posted
Related Studies
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
This study has been completed.
Study NCT00094549   Information provided by Eli Lilly and Company

First Received on October 20, 2004.   Last Updated on January 24, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bipolar Disorder
More general conditions related to this trial
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Interventions listed in this trial
olanzapine
divalproex sodium
placebo
Additional drug interventions recognized in this trial
Valproic Acid
More general drug interventions related to this trial
Anticonvulsants
Antiemetics
Antimanic Agents
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services